Literature DB >> 24911119

PRMT2 and RORγ expression are associated with breast cancer survival outcomes.

Tae Gyu Oh1, Peter Bailey, Eloise Dray, Aaron G Smith, Joel Goode, Natalie Eriksson, John W Funder, Peter J Fuller, Evan R Simpson, Wayne D Tilley, Peter J Leedman, Christine L Clarke, Sean Grimmond, Dennis H Dowhan, George E O Muscat.   

Abstract

Protein arginine methyltransferases (PRMTs) methylate arginine residues on histones and target transcription factors that play critical roles in many cellular processes, including gene transcription, mRNA splicing, proliferation, and differentiation. Recent studies have linked PRMT-dependent epigenetic marks and modifications to carcinogenesis and metastasis in cancer. However, the role of PRMT2-dependent signaling in breast cancer remains obscure. We demonstrate PRMT2 mRNA expression was significantly decreased in breast cancer relative to normal breast. Gene expression profiling, Ingenuity and protein-protein interaction network analysis after PRMT2-short interfering RNA transfection into MCF-7 cells, revealed that PRMT2-dependent gene expression is involved in cell-cycle regulation and checkpoint control, chromosomal instability, DNA repair, and carcinogenesis. For example, PRMT2 depletion achieved the following: 1) increased p21 and decreased cyclinD1 expression in (several) breast cancer cell lines, 2) decreased cell migration, 3) induced an increase in nucleotide excision repair and homologous recombination DNA repair, and 4) increased the probability of distance metastasis free survival (DMFS). The expression of PRMT2 and retinoid-related orphan receptor-γ (RORγ) is inversely correlated in estrogen receptor-positive breast cancer and increased RORγ expression increases DMFS. Furthermore, we found decreased expression of the PRMT2-dependent signature is significantly associated with increased probability of DMFS. Finally, weighted gene coexpression network analysis demonstrated a significant correlation between PRMT2-dependent genes and cell-cycle checkpoint, kinetochore, and DNA repair circuits. Strikingly, these PRMT2-dependent circuits are correlated with pan-cancer metagene signatures associated with epithelial-mesenchymal transition and chromosomal instability. This study demonstrates the role and significant correlation between a histone methyltransferase (PRMT2)-dependent signature, RORγ, the cell-cycle regulation, DNA repair circuits, and breast cancer survival outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911119      PMCID: PMC5414829          DOI: 10.1210/me.2013-1403

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  59 in total

1.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

2.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models.

Authors:  Markus S Schröder; Aedín C Culhane; John Quackenbush; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2011-09-07       Impact factor: 6.937

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 4.  Arginine methylation an emerging regulator of protein function.

Authors:  Mark T Bedford; Stéphane Richard
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

Review 5.  ERα-associated protein networks.

Authors:  Jennifer R Schultz-Norton; Yvonne S Ziegler; Ann M Nardulli
Journal:  Trends Endocrinol Metab       Date:  2011-03-02       Impact factor: 12.015

6.  A fuzzy gene expression-based computational approach improves breast cancer prognostication.

Authors:  Benjamin Haibe-Kains; Christine Desmedt; Françoise Rothé; Martine Piccart; Christos Sotiriou; Gianluca Bontempi
Journal:  Genome Biol       Date:  2010-02-15       Impact factor: 13.583

7.  A recurrent mutation in PALB2 in Finnish cancer families.

Authors:  Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist
Journal:  Nature       Date:  2007-02-07       Impact factor: 49.962

8.  The humoral immune system has a key prognostic impact in node-negative breast cancer.

Authors:  Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 9.  The spindle-assembly checkpoint in space and time.

Authors:  Andrea Musacchio; Edward D Salmon
Journal:  Nat Rev Mol Cell Biol       Date:  2007-04-11       Impact factor: 94.444

10.  Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.

Authors:  Julia Eschenbrenner; Sebastian Winsel; Stefanie Hammer; Anette Sommer; Kevin Mittelstaedt; Michael Drosch; Ulrich Klar; Christoph Sachse; Michael Hannus; Monika Seidel; Bertram Weiss; Claudia Merz; Gerhard Siemeister; Jens Hoffmann
Journal:  Front Oncol       Date:  2011-11-16       Impact factor: 6.244

View more
  23 in total

Review 1.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

2.  Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.

Authors:  Lakshmi Prabhu; Lan Chen; Han Wei; Özlem Demir; Ahmad Safa; Lifan Zeng; Rommie E Amaro; Bert H O'Neil; Zhon-Yin Zhang; Tao Lu
Journal:  Mol Biosyst       Date:  2017-11-21

3.  Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.

Authors:  Molly M Morgan; Lisa M Arendt; Elaine T Alarid; David J Beebe; Brian P Johnson
Journal:  FASEB J       Date:  2019-04-19       Impact factor: 5.191

Review 4.  Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

Authors:  Ewa M Michalak; Jane E Visvader
Journal:  Mol Oncol       Date:  2016-09-23       Impact factor: 6.603

5.  Stigmasterol inhibits the progression of lung cancer by regulating retinoic acid-related orphan receptor C.

Authors:  Yuan Dong; Congcong Chen; Chen Chen; Chunxia Zhang; Lei Zhang; Yan Zhang; Yongliang Li; Zhiqiang Dong
Journal:  Histol Histopathol       Date:  2021-10-29       Impact factor: 2.303

6.  Identification of RORγ as a favorable biomarker for colon cancer.

Authors:  Xiaofei Pan; Bao Li; Gan Zhang; Yuyong Gong; Rui Liu; Benxin Chen; Yang Li
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

Review 7.  Protein arginine methylation/demethylation and cancer.

Authors:  Coralie Poulard; Laura Corbo; Muriel Le Romancer
Journal:  Oncotarget       Date:  2016-10-11

Review 8.  Protein arginine methylation: an emerging regulator of the cell cycle.

Authors:  Anita E Raposo; Sabine C Piller
Journal:  Cell Div       Date:  2018-03-20       Impact factor: 5.130

9.  The Nuclear Receptor, RORγ, Regulates Pathways Necessary for Breast Cancer Metastasis.

Authors:  Tae Gyu Oh; Shu-Ching M Wang; Bipul R Acharya; Joel M Goode; J Dinny Graham; Christine L Clarke; Alpha S Yap; George E O Muscat
Journal:  EBioMedicine       Date:  2016-02-18       Impact factor: 8.143

10.  RORα and RORγ expression inversely correlates with human melanoma progression.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Cezary Skobowiat; Anton Jetten; Andrzej T Slominski
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.